Nxera PharmaNxera Pharma Co., Ltd.4565東証プライム医薬品FY ending Dec 2023, consolidated, IFRS

Nxera Pharma FY ending Dec 2023 results

Nxera Pharma brought in ¥12.8B in revenue.

Revenue changed -18.0% from the prior year.

What changed from last year

FY ending Dec 2022 → FY ending Dec 2023

FY ending Dec 2022 → FY ending Dec 2023

※ Cost of revenue is not disclosed; expenses are combined

※ Operating income is not disclosed; the chart goes straight to pretax income including investment gains

A machine-readable operating income value exists, but it is not in the validated published data, so the chart is omitted.

Show source documents (4)

EDINET (FSA Japan)
有価証券報告書－第36期(2025/01/01－2025/12/31)
ID S100XTYN2026-03-25Open
EDINET (FSA Japan)
有価証券報告書－第33期(2022/01/01－2022/12/31)
ID S100QFQ72023-03-23Open
EDINET (FSA Japan)
有価証券報告書－第32期(令和3年1月1日－令和3年12月31日)
ID S100NQA22022-03-24Open
EDINET (FSA Japan)
有価証券報告書－第31期(令和2年1月1日－令和2年12月31日)
ID S100L0R42021-03-24Open

Extracted from XBRL: 10 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.